Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma
Open Access
- 21 August 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (8) , e009642
Abstract
Background: Immune escape is an important feature of hepatocellular carcinoma (HCC). The overall response rate of immune checkpoint inhibitors (ICIs) in HCC is still limited. Revealing the immune regulation mechanisms and finding new immune targets are expected to further improve the efficacy of immunotherapy. Our study aims to use CRISPR screening mice models to identify potential targets that play a critical role in HCC immune evasion and further explore their value in improving immunotherapy. Methods: We performed CRISPR screening in two mice models with different immune backgrounds (C57BL/6 and NPG mice) and identified the immunosuppressive gene Gsk3a as a candidate for further investigation. Flow cytometry was used to analyze the impact of Gsk3a on immune cell infiltration and T-cell function. RNA sequencing was used to identify the changes in neutrophil gene expression induced by Gsk3a and alterations in downstream molecules. The therapeutic value of the combination of Gsk3a inhibitors and anti-programmed cell death protein-1 (PD-1) antibody was also explored. Results: Gsk3a, as an immune inhibitory target, significantly promoted tumor growth in immunocompetent mice rather than immune-deficient mice. Gsk3a inhibited cytotoxic T lymphocytes (CTLs) function by inducing neutrophil chemotaxis. Gsk3a promoted self-chemotaxis of neutrophil expression profiles and neutrophil extracellular traps (NETs) formation to block T-cell activity through leucine-rich α-2-glycoprotein 1 (LRG1). A significant synergistic effect was observed when Gsk3a inhibitor was in combination with anti-PD-1 antibody. Conclusions: We identified a potential HCC immune evasion target, Gsk3a, through CRISPR screening. Gsk3a induces neutrophil recruitment and NETs formation through the intermediate molecule LRG1, leading to the inhibition of CTLs function. Targeting Gsk3a can enhance CTLs function and improve the efficacy of ICIs.Keywords
This publication has 49 references indexed in Scilit:
- FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2Journal of Hepatology, 2023
- Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCCHepatology, 2022
- In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy targetCell, 2021
- Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesisCell, 2021
- AAV‐mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune responseMolecular Oncology, 2020
- CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune CytotoxicityImmunity, 2020
- Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell SequencingCell, 2017
- The Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentCancer Microenvironment, 2014
- Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post‐lactational regressionThe Journal of Pathology, 2011
- Dynamics of Neutrophil Migration in Lymph Nodes during InfectionImmunity, 2008